Global HPV Testing Market 2016-2020
About HPV Testing
According to Centers for Disease Control and Prevention (CDC), human papillomavirus (HPV) refers to a group of more than 100 related viruses that commonly cause infections and do not have any symptoms. Among these, more than 40 types of HPVs cause highly contagious diseases that are transmitted through direct sexual contact, infecting both male and female genitals. The other types of HPV cause non-genital warts that are not sexually transmitted. Though most HPV infections are harmless and heal on their own, certain high-risk types of genital HPV can be persistent and cause cervical, penile, anal, vaginal, and oropharyngeal cancers. Many individuals, especially women, undergo regular HPV tests as a preventive measure. HPV tests help to detect the viral genetic material in a cell sample taken from the cervix.
Technavio’s analysts forecast the global HPV testing market to grow at a CAGR of 16.17% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global HPV testing market for 2016-2020. To calculate the market size, the report considers only the HPV test products used for genital cancer screening such as cervical cancer.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global HPV Testing Market 2016-2020
Technavio recognizes the following companies as the key players in the global HPV testing market: Abbott Laboratories, BD, Roche Diagnostics, and Qiagen
Other Prominent Vendors in the market are: Arbor Vita, Breakspear Medical, Cepheid, DAAN Gene, DiaCarta, Delphi Bioscience, Fujirebio Diagnostics, Genera Biosystems, IncellDx, OralDNA Labs, Seegene, SoloPap, and Trovagene
Commenting on the report, an analyst from Technavio’s team said: “HPV and Pap tests help to detect cervical cancer in women. The Pap test identifies changes in cervical cells caused by HPV infection. The HPV test is used to check for HPV genotypes in sample cells. A physician may advise a patient to undergo both HPV and Pap tests for the screening of cervical cancer. The American Cancer Society, the US Preventive Services Task Force, the American Society for Clinical Pathology, and the American Society for Colposcopy and Cervical Pathology have provided guidelines for the testing of cervical cancer in women in the US. These guidelines state that women aged 30-65 years should undergo Pap and HPV co-testing every five years or undergo Pap test every three years.”
According to the report, vendors in the market have developed innovative home-based products that provide quick and accurate test results. This can help to reduce the cost burden on patients and keep cervical cancer at bay. The adoption of HPV home testing kits is growing developing countries owing to increasing awareness, which is striving the market growth.
Further, the report states that HPV screening test is adopted by many healthcare centers as it can predict the risk of cervical cancer. The result can be positive or negative. If positive, then the individual has to undergo Pap test or colposcopy. Through Pap test, the physician can understand the presence of abnormal or precancerous cells in the cervix. HPV test is a better predictor of low cervical cancer risk; however Pap test can be more efficient in those cases. Based on sensitivity and specificity, Pap test is adopted more than HPV testing.
Abbott Laboratories, BD, Roche Diagnostics, Qiagen, Arbor Vita, Breakspear Medical, Cepheid, DAAN Gene, DiaCarta, Delphi Bioscience, Fujirebio Diagnostics, Genera Biosystems, IncellDx, OralDNA Labs, Seegene, SoloPap, Trovagene.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook